Hydroxyurea-Increased Fetal Hemoglobin Is Associated with Less Organ Damage and Longer Survival in Adults with Sickle Cell Anemia
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Adults with sickle cell anemia (HbSS) are inconsistently treated with hydroxyurea. OBJECTIVES: We retrospectively evaluated the effects of elevating fetal hemoglobin with hydroxyurea on organ damage and survival in patients enrolled in our screening study between 2001 and 2010. METHODS: An electronic medical record facilitated development of a database for comparison of study parameters based on hydroxyurea exposure and dose. This study is registered with ClinicalTrials.gov, number NCT00011648. RESULTS: Three hundred eighty-three adults with homozygous sickle cell disease were analyzed with 59 deaths during study follow-up. Cox regression analysis revealed deceased subjects had more hepatic dysfunction (elevated alkaline phosphatase, Hazard Ratio = 1.005, 95% CI 1.003-1.006, p<0.0.0001), kidney dysfunction (elevated creatinine, Hazard Ratio = 1.13, 95% CI 1.00-1.27, p = 0.043), and cardiopulmonary dysfunction (elevated tricuspid jet velocity on echocardiogram, Hazard Ratio = 2.22, 1.23-4.02, p = 0.0082). Sixty-six percent of subjects were treated with hydroxyurea, although only 66% of those received a dose within the recommended therapeutic range. Hydroxyurea use was associated with improved survival (Hazard Ratio = 0.58, 95% CI 0.34-0.97, p = 0.040). This effect was most pronounced in those taking the recommended dose of 15-35 mg/kg/day (Hazard Ratio 0.36, 95% CI 0.17-0.73, p = 0.0050). Hydroxyurea use was not associated with changes in organ function over time. Further, subjects with higher fetal hemoglobin responses to hydroxyurea were more likely to survive (p = 0.0004). While alkaline phosphatase was lowest in patients with the best fetal hemoglobin response (95.4 versus 123.6, p = 0.0065 and 96.1 versus 113.6U/L, p = 0.041 at first and last visits, respectively), other markers of organ damage were not consistently improved over time in patients with the highest fetal hemoglobin levels. CONCLUSIONS: Our data suggest that adults should be treated with the maximum tolerated hydroxyurea dose, ideally before organ damage occurs. Prospective studies are indicated to validate these findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased HbF associated with taking 15 to 35 mg/kg hydroxyurea improved survival in 393 HbS homozygotes (HR: 0.36; 95% CI: 0.17-0.73).62”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [62]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320 · cited 5×
“It is possible that HbF approaching 30% may be crucial to prevent organ injury and vascular damage [2].”
BackgroundResultInfluentialEffect of hydroxyurea on the frequency of painful crises in sickle cell anemia
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322001 · Cited by 2,340 · cited 2×
“0001 at last visit in subjects taking versus not taking hydroxyurea), the value was considerably above the ANC of 2,000u/L which defines the maximum tolerated dose [10].”
BackgroundPulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease
Gladwin, M. T., Sachdev, V., Jison, M. L., Shizukuda, Y., Plehn, J. F., Minter, K., Brown, B., Coles, W. A., Nichols, J. S., Ernst, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035477 · Cited by 1,325
Self-citationPathogenesis and Treatment of Sickle Cell Disease
Bunn, H. F. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371107 · Cited by 1,154 · cited 1×
“Homozygous sickle cell disease (HbSS) leads to polymerization of deoxygenated sickle hemoglobin within rigid red blood cells (RBC) which then occlude microvasculature, resulting in acute complications, chronic organ damage, and premature death [1].”
BackgroundWang, W. C., Ware, R. E., Miller, S. T., Iyer, R. V., Casella, J. F., Minniti, C. P., Rana, S., Thornburg, C. D., Rogers, Z. R., Kalpatthi, R. V., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60355-3 · Cited by 803 · cited 1×
“A randomized study of fixed dose hydroxyurea (20 mg/kg/day versus placebo) in infants with HbSS showed improvement in markers of splenic function, suggesting that even modest HbF increases can be beneficial [28].”
BackgroundSelf-citationOutcome of Sickle Cell Anemia: A 4-Decade Observational Study of 1056 Patients
Powars, D. R., Chan, L. S., Hiti, A., Ramicone, E., & Johnson, C. (2005) · Medicine · doi:10.1097/01.md.0000189089.45003.52 · Cited by 558 · cited 1×
“This contrasts a four decade observational study, where most deaths were associated with irreversible end organ damage [3].”
BackgroundHydroxyurea enhances fetal hemoglobin production in sickle cell anemia.
Platt, O. S., Orkin, S. H., Dover, G., Beardsley, G. P., Miller, B., & Nathan, D. G. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111464 · Cited by 535 · cited 1×
“The MSH did not specifically report fetal hemoglobin (HbF) responses, although other reports have shown that hydroxyurea largely exerts its effect by increasing HbF and inhibiting RBC sickling [11,12].”
BackgroundThe risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up
Steinberg, M. H., McCarthy, W. F., Castro, O., Ballas, S. K., Armstrong, F. D., Smith, W., Ataga, K., Swerdlow, P., Kutlar, A., DeCastro, L., et al. (2010) · American Journal of Hematology · doi:10.1002/ajh.21699 · Cited by 486 · cited 3×
“Long-term hydroxyurea studies suggest improved survival [7,8,14].”
Voskaridou, E., Christoulas, D., Bilalis, A., Plata, E., Varvagiannis, K., Stamatopoulos, G., Sinopoulou, K., Balassopoulou, A., Loukopoulos, D., & Terpos, E. (2010) · Blood · doi:10.1182/blood-2009-05-221333 · Cited by 430 · cited 4×
“First, laboratory studies indicating a more severe phenotype, including lower HbF and higher WBC and LDH values, were significantly different prior to death compared to those still living [2,8].”
BackgroundResultInfluentialMortality Rates and Age at Death from Sickle Cell Disease: U.S., 1979–2005
Lanzkron, S., Carroll, C. P., & Haywood, C. (2013) · Public Health Reports® · doi:10.1177/003335491312800206 · Cited by 414 · cited 1×
“Health database studies have shown no change in mortality since hydroxyurea approval [9,17], and recent studies have shown no association between current hydroxyurea use and mortality [16,18,19].”
Background
Research works printed but not linked: 2
- (2012) Hydroxyurea Drug Label. Bristol-Myers Squibb Company pp. 1– 13.
- Nottage K, Ware R, Winter B, Winfred W, Hankins J, Shulkin B, et al (2013) Hydroxyurea Preserves Splenic Function Among Children with Sickle Cell Anemia. Pediatric Blood and Cancer 60 Supplement 2: S24– S24.
Cited by
Piel, F. B., Rees, D. C., DeBaun, M. R., Nnodu, O., Ranque, B., Thompson, A. A., Ware, R. E., Abboud, M. R., Abraham, A., Ambrose, E. E., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(23)00096-0 · Cited by 177
Fetal hemoglobin in sickle cell anemia
Steinberg, M. H. (2020) · Blood · doi:10.1182/blood.2020007645 · Cited by 136
Fitzhugh, C. D., Hsieh, M. M., Taylor, T., Coles, W., Roskom, K., Wilson, D., Wright, E., Jeffries, N., Gamper, C. J., Powell, J., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016002972 · Cited by 105
“The majority of patients experience a poor quality of life and significantly reduced lifespan.(1,2,4) The most readily available curative option remains allogeneic hematopoietic stem cell transplantation (HSCT).”
BackgroundSelf-citationPecker, L. H., & Lanzkron, S. (2021) · Annals of Internal Medicine · doi:10.7326/aitc202101190 · Cited by 112
Qureshi, A., Kaya, B., Pancham, S., Keenan, R., Anderson, J., Akanni, M., Howard, J., & the British Society for Haematology (2018) · British Journal of Haematology · doi:10.1111/bjh.15235 · Cited by 104
Guilcher, G. M. T., Truong, T. H., Saraf, S. L., Joseph, J. J., Rondelli, D., & Hsieh, M. M. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.04.011 · Cited by 73
“Risks and long-term complications of HCT have decreased over time but the median age of death for adult individuals with SCD has remained in the 4th to 5th decade of life (33, 34), and the comparative risk ratio vis-à-vis medical management has gradually shifted in favor of HCT.”
BackgroundSelf-citationHeitzer, A. M., Longoria, J. N., Okhomina, V. I., Wang, W. C., Raches, D., Potter, B., Jacola, L. M., Porter, J. S., Schreiber, J. E., King, A. A., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17687 · Cited by 67
Risks associated with fertility preservation for women with sickle cell anemia
Pecker, L. H., Maher, J. Y., Law, J. Y., Beach, M. C., Lanzkron, S., & Christianson, M. S. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.05.016 · Cited by 57
“The decision to provide simple or exchange transfusions is made based on hemoglobin level and transfusion indication (56).”
BackgroundKinetic assay shows that increasing red cell volume could be a treatment for sickle cell disease
Li, Q., Henry, E. R., Hofrichter, J., Smith, J. F., Cellmer, T., Dunkelberger, E. B., Metaferia, B. B., Jones-Straehle, S., Boutom, S., Christoph, G. W., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1619054114 · Cited by 47
“Proc Natl Acad Sci USA 73(9):3035–3039.”
BackgroundSelf-citationShah, N., Lipato, T., Alvarez, O. A., Delea, T. E., Lonshteyn, A., Weycker, D. A., Nguyen, A., Beaubrun, A. C., & Agodoa, I. (2022) · Expert Review of Hematology · doi:10.1080/17474086.2022.2031967 · Cited by 39
“When considering chronic complications related to SCD, hydroxyurea is also a treatment option, but patients receiving this treatment still experience anemia, organ damage, and early mortality [14].”
BackgroundUchida, N., Fujita, A., Hsieh, M. M., Bonifacino, A. C., Krouse, A. E., Metzger, M. E., Donahue, R. E., & Tisdale, J. F. (2017) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.029 · Cited by 34
“1,2 However, responses to HU are variable, with most patients experiencing only modest improvements in their health, and HU must be continuously administered to maintain therapeutic benefit.”
Self-citationParrow, N. L., Tu, H., Nichols, J., Violet, P.-C., Pittman, C. A., Fitzhugh, C. D., Fleming, R. E., Mohandas, N., Tisdale, J. F., & Levine, M. (2017) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2017.04.005 · Cited by 30
Self-citationJosé, J., Elsadek, R. A., Jimmy, B., & George, P. (2019) · Oman Medical Journal · doi:10.5001/omj.2019.64 · Cited by 26
“Arch Intern Med 2007 Sep;167(16):1798-1803.”
Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Sickle Cell Disease
Saraf, S. L., & Rondelli, D. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101565 · Cited by 29
“Several cohorts have demonstrated that long-term use of hydroxyurea may lead to improved survival patterns, particularly in those that have a high hemoglobin F response, although its effects on chronic organ damage are less clear [13,40,41].”
BackgroundFitzhugh, C. D., & Walters, M. C. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017007708 · Cited by 24
“Although HU has been shown to significantly improve acute complications such as vaso-occlusive crises and acute chest syndrome in children of all ages,(13-16) there are challenges with HU adherence over the long term,(17) and HU has not been shown to prevent the organ damage that is associated with early mortality in…”
BackgroundSelf-citationMohammad, S. N. N. A., Iberahim, S., Rahman, W. S. W. A., Hassan, M. N., Edinur, H. A., Azlan, M., & Zulkafli, Z. B. (2022) · Diagnostics · doi:10.3390/diagnostics12061374 · Cited by 27
“Ribonucleotide reductase is inhibited, thus blocking DNA synthesis, leading to cellular cytotoxicity and suppression of erythroid progenitors, which affects the erythropoiesis kinetics and physiology and leads to recruitment of erythroid progenitors with increased HbF levels [26,28,30,32,33].”
BackgroundPecker, L. H., Kappa, S. S., Greenfest, A., Darbari, D. S., & Nickel, R. S. (2018) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2018.05.019 · Cited by 20
“Hydroxyurea treatment decreases pain and acute chest syndrome (ACS) events in children with SCA(2,3) and is associated with improved cerebrovascular health, growth, health-related quality of life, and survival.(4-15) In 2002, the National Heart, Lung, and Blood Institute (NHLBI) recommended hydroxyurea for children wi…”
Venkatesan, V., Christopher, A. C., Rhiel, M., Azhagiri, M. K. K., Babu, P., Walavalkar, K., Saravanan, B., Andrieux, G., Rangaraj, S., Srinivasan, S., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.04.024 · Cited by 20
“Morbidity in b-thalassemia and SCD patients is inversely correlated with the levels of fetal hemoglobin (HbF) in adulthood.(6,7) Expression of g-globin, the fetal b-like globin component of HbF, improves the globin chain equilibrium and thus prevents apoptosis of erythroid cells in b-thalassemia.”
BackgroundHankins, J. S., Brambilla, D. J., Potter, M. B., Kutlar, A., Gibson, R. W., King, A. A., Baumann, A. A., Melvin, C. L., Gordeuk, V. R., Hsu, L. L.-Y., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010670 · Cited by 20
“1 Hydroxyurea can reduce the frequency of acute events, 2 preserve organ function, 3 improve quality of life (QoL), 4 increase survival, 5,6 and reduce health care expenditures.”
BackgroundBernaudin, F. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101523 · Cited by 23
“Tricuspid regurgitant jet velocity (TRJV) associated with NT-proBNP and the 6-minute walk test are useful to detect patients at risk of pulmonary hypertension, which is mainly diagnosed as a mean pulmonary artery pressure (mPAP) > 25 mm Hg by right heart catheterization; however, TRJV > 2.5 m/s was shown to a be a ris…”
BackgroundInfluentialChambers, T. M., Kahan, S., Camanda, J., Scheurer, M. E., & Airewele, G. E. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27365 · Cited by 17
Limerick, E. M., & Fitzhugh, C. D. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111997 · Cited by 15
“We recently reported a median age at death of 46 years for adults with SCD [3].”
BackgroundSelf-citationClinical Manifestations of Sickle Cell Disease Across the Lifespan
Pecker, L. H., & Little, J. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-62328-3_1 · Cited by 18
Fitzhugh, C. D., Volanakis, E. J., Idassi, O. M., Duberman, J. A., DeBaun, M. R., & Friedman, D. L. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11113118 · Cited by 14
Self-citationAkingbola, T. S., Tayo, B. O., Ezekekwu, C. A., Sonubi, O., Zhang, X., Saraf, S. L., Molokie, R. E., Hsu, L. L.-Y., Han, J., Cooper, R., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25412 · Cited by 13
Minireview: Prognostic factors and the response to hydroxurea treatment in sickle cell disease
Wang, W. C. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216642048 · Cited by 13
“In a recent review of 383 adults with HbSS from the NIH, there were 59 deaths, which were significantly related to hepatic, kidney, and cardiopulmonary dysfunction.(36) HU use was associated with improved survival, particularly in those taking the recommended dose of 15–35 mg/kg/d (hazard ratio 0.”
BackgroundEnd Organ Affection in Sickle Cell Disease
Bathla, T., Lotfollahzadeh, S., Quisel, M. J., Mehta, M., Malikova, M. A., & Chitalia, V. C. (2024) · Cells · doi:10.3390/cells13110934 · Cited by 13
“Fitzhugh et al. [15] noted a statistically significant association between the use of hydroxyurea (an agent known to increase HbF levels, vide infra) and decreased mortality. increase HbF levels, vide infra) and decreased mortality.”
BackgroundManagement of Kidney Disease with Sickle Cell Disease
Abbasi, M., Srivastava, A., & Saraf, S. L. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000804 · Cited by 11
Cronin, R. M., Wuichet, K., Ghafuri, D. L., Hodges, B., Chopra, M., He, J., Niu, X., Kassim, A. A., Wilkerson, K., Rodeghier, M., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022008692 · Cited by 12
“However, prescription history is a reasonable approach for disease-modifying treatment assignment and is similar to previous large cohorts showing hydroxyurea therapy to be associated with a survival benefit.(19,22,24,26) Second, we could not account for hydroxyurea prescriptions outside of VUMC.”
Fetal hemoglobin modulates neurocognitive performance in sickle cell anemia✰,✰✰
Heitzer, A. M., Longoria, J. N., Rampersaud, E., Rashkin, S. R., Estepp, J. H., Okhomina, V. I., Wang, W. C., Raches, D., Potter, B., Steinberg, M. H., et al. (2022) · Current Research in Translational Medicine · doi:10.1016/j.retram.2022.103335 · Cited by 11
Recent progress in the treatment of sickle cell disease: an up-to-date review
Acharya, B., Mishra, D. P., Barik, B., Mohapatra, R. K., & Sarangi, A. K. (2023) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1186/s43088-023-00373-w · Cited by 15
RNA Trans-Splicing Targeting Endogenous β-Globin Pre-Messenger RNA in Human Erythroid Cells
Uchida, N., Washington, K. N., Mozer, B. A., Platner, C., Ballantine, J., Skala, L. P., Raines, L. N., Shvygin, A., Hsieh, M. M., Mitchell, L. G., et al. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.077 · Cited by 8
“However, lifelong intake at a sufficient dose is required to maintain the beneficial hematologic effects.(1,2) In contrast, one-time cures using hematopoietic stem cell (HSC)-based therapies, including allogeneic HSC transplantation and HSC-targeted gene therapy, are increasingly accessible to affected patients.”
Self-citationPatel, D. A., Akinsete, A. M., Connelly, J. A., & Kassim, A. A. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1642103 · Cited by 10
Jacobs, C., Liu, A., McCrary, B., McCuskee, S., Wexler, M. G., Stidham, E., Zhang, B., Glassberg, J., & Curtis, S. (2025) · Pain Management Nursing · doi:10.1016/j.pmn.2025.04.012 · Cited by 7
Awa, H. D. M., Dongmo, F., Sap, S. N. U., Fonkwo, V., Yanda, A. A., Nlend, A. E. N., Ndombo, P. O. K., & Tchokoteu, P. F. (2017) · HEALTH SCIENCES AND DISEASE · doi:10.5281/hsd.v18i4.943 · Cited by 6
Adding hydroxyurea to chronic transfusion therapy for sickle cell anemia reduces transfusion burden
Nickel, R. S., Margulies, S., Panchapakesan, K., Chorvinsky, E. A., Niño, G., Gierdalski, M., Bost, J. E., Luban, N. L. C., & Webb, J. L. (2024) · Transfusion · doi:10.1111/trf.18073 · Cited by 9
Moser, B. A., LaBell, E. S., Chigutsa, E., Jakubowski, J. A., & Small, D. S. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0556-y · Cited by 5
“While hydroxyurea treatment can provide significant benefits regarding rates of pain, acute chest syndrome, hospitalizations, and transfusions, decreases in markers of organ damage appear to vary [7].”
BackgroundInnovations in Targeted Anti‐Adhesion Treatment for Sickle Cell Disease
Kanter, J., & Lanzkron, S. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1682 · Cited by 5
“Included in these impediments have been clinical trials which failed to meet enrollment, trials that failed to meet necessary end points, and the more concerning issues of limited funding and national advocacy due in part to disease-specific stigmatism.25 Table 1 includes a breakdown of recent clinical trials of anti-…”
BackgroundInfluentialEllison, V. N., Berlin, K. S., Longoria, J. N., Potter, B., Raches, D., Hankins, J. S., Takemoto, C. M., & Heitzer, A. M. (2024) · Journal of Pediatric Psychology · doi:10.1093/jpepsy/jsae029 · Cited by 5
Pecker, L. H., Silver, E. J., Roth, M. E., & Manwani, D. G. (2020) · Journal of Health Care for the Poor and Underserved · doi:10.1353/hpu.2020.0030 · Cited by 5
Oldham, M., Conrey, A. K., Pittman, C. A., Fisher, C., Hargrett, S., West, K. A., Jackson, M., Martin, S. C., Hsieh, M. M., Jeffries, N. O., et al. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1699 · Cited by 4
Self-citationIntensive hydroxyurea dosing in very young children with sickle cell anemia
Wang, W. C., Brown, C., McNaull, M. A., Rogers, Z. R., Barton, M., Dua, M., Hankins, J. S., Gossett, J. M., Richardson, J. L., Porter, J. S., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009613 · Cited by 3
Organ involvement occurs in all forms of hereditary haemolytic anaemia
van Straaten, S., Verhoeven, J., Hagens, S., Schutgens, R. E. G., van Solinge, W. W., van Wijk, R., & van Beers, E. J. (2018) · British Journal of Haematology · doi:10.1111/bjh.15575 · Cited by 3
An Overview of Solid Organ Transplantation in Patients With Sickle Cell Disease
Sharpe, C. C., Suddle, A. R., & Stuart‐Smith, S. (2022) · Transplantation · doi:10.1097/tp.0000000000004305 · Cited by 5
“HC use is not associated with improvement in organ function in adults; therefore, treatment should be started in childhood, before organ damage occurs.(50)”
BackgroundAbuAlhommos, A. K., Hawaj, M. A. A., Alshams, H. M., Aljafary, M. A., Alhuwail, S. K., & Alfuhaid, Y. (2026) · Medicine · doi:10.1097/md.0000000000046958 · Cited by 2
“[39] Moreover, multiple prior studies show hydroxyurea enhances hematological and clinical characteristics for SCA patients, [40–43] with notable improvement in survival [44] and some QoL measures, [18] Table 2 Patients’ quality of life profile.”
Pulmonary Hypertension Among Individuals Living With Hemoglobinopathies: A Systematic Review
Okeke, C. C., Ojo, A., Okere, M. O., Ebiliekwe, O. E., Ekeocha, I. R., Idion, K. N., Egemonye, O., Alli, O. O., Ugo-Ihanetu, E. A., Okorienta, S., et al. (2025) · Cureus · doi:10.7759/cureus.88234 · Cited by 1
“Hydroxyurea has been associated with reduced hemolysis and improved endothelial function [35], suggesting a potentially protective role against pulmonary hypertension that was not sufficiently explored in the included studies.”
Limerick, E. M., Hsieh, M. M., Queen, J., Grecco, M. L., Varga, J., Brooks, J., Coles, W. A., Jeffries, N. O., & Fitzhugh, C. D. (2026) · PLoS ONE · doi:10.1371/journal.pone.0332282 · Cited by 1
Self-citationEngels, T., Waskiewicz, K., Glineur, R., & Oth, O. (2019) · Revue Medicale de Bruxelles · doi:10.30637/2019.18-047 · Cited by 1
Mohammadi, Z., Mohammadi, R., Haghpanah, S., Moghadam, M., Pazhoomand, R., & Karimi, M. (2020) · Hemoglobin · doi:10.1080/03630269.2020.1845722 · Cited by 1
de Araújo, O. M. R., Ivo, M. L., de Souza, A. S., Guerrero, A. T. G., Carvalho, A. M. A., de Miranda, F. R., Marcheti, M. A., Neto, A. T. D. S., Melo, E. S. D. P., de Azevedo, I. C., et al. (2016) · International Archives of Medicine · doi:10.3823/2220 · Cited by 1
“Such changes occur in cell morphology, and the RBCs are an elongate form known as “sickle erythrocyte” altering the rheology of red blood cells and the erythrocyte membrane and results in the polymerization phenomenon [3, 4].”
BackgroundFigueiredo, L. M., Morrone, K. A., Wei, C., Ireland, K., Cohen, H. W., Driscoll, C., & Manwani, D. G. (2017) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2017.07.004
Ingram, C. (2018) · Open University of Cape Town (University of Cape Town) · Cited by 1
Neto, O. S. D., Silva, K. S. F. E., Barbosa, A. M., Rodrigues, D. A., Lagares, M. H., da Costa, I. R., & Moura, K. K. V. O. (2019) · Genetics and Molecular Research · doi:10.4238/gmr18200
Shaw, R. S., Kappa, S. S., & Nickel, R. S. (2019) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000001638
Impact of Hydroxyurea Starting Dose on Pain Outcomes in Patients with Sickle Cell Disease
Dayer, L. E., Wagner, R., King, D., Lakkad, M., Wilson, L. A., Montgomery, C., & Painter, J. T. (2022) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/15360288.2022.2128154
“Additional benefits include prolonged survival and decreased organ damage (3).”
BackgroundStocco, D. C. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2022.tde-03022023-150353
Sickle cell disease: causes, treatments and the patient experience
Spurway, A., George, S., Thompson, C., Weeks, S., & Teo, X. Y. (2024) · Pharmaceutical journal/The pharmaceutical journal · doi:10.1211/pj.2023.1.205570
Queen, J., Limerick, E. M., Jeffries, N. O., Hsieh, M. M., Shamburek, R. D., & Fitzhugh, C. D. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.12.008
Self-citationFluid mechanics of thin blood films to detect anemia and sickle cell disease
Mir, M. A., Tirumkudulu, M. S., & Raicha, B. (2026) · Lab on a Chip · doi:10.1039/d5lc00943j
Déterminants de la réponse à l'Hydroxyurée au cours du traitement de la drépanocytose
Rakotoson, M. G. (2016) · theses.fr (ABES) · doi:10.70675/29250363zfe0bz41aaz860azcc473ae41b1f · Cited by 1
HbF/F-cell and the Phenotype of Sickle Cell DiseasePreprint
Lofters, J., Wilks, A., Lee, J. W., Hicks, J. M., Klings, E. S., & Steinberg, M. H. (2026) · medRxiv · doi:10.64898/2026.06.02.26354737
AlJohani, N. I., Almasari, A., Shihata, N., Usman, B., Eisa, N., Abbas, S., Jaha, R., Zabani, R., Salameh, A. R., Qureshi, R., et al. (2026) · Bone Marrow Transplantation · doi:10.1038/s41409-026-02965-3
Perspective Chapter: Fetal Hemoglobin Modulators
Walke, V. A. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1017037
Metadata
- Authors
- Fitzhugh, C. D., Hsieh, M. M., Allen, D., Coles, W. A., Seamon, C., Ring, M., Zhao, X., Minniti, C. P., Rodgers, G. P., Schechter, A. N., Tisdale, J. F., & Taylor, J. G.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Taylor, James G.
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-11-17
- Volume
- 10
- Issue
- 11
- Pages
- e0141706
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4648496
- OpenAlex
- W2174941367
- Semantic Scholar
- 80467cdbafaf1aba24e6bceb076ceb4177a49c7c
- Cited by
- 64
- References
- 31
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 5 · 2023: 5 · 2022: 9 · 2021: 2 · 2020: 4 · 2019: 10 · 2018: 6 · 2017: 10 · 2016: 3
- FWCI
- 3.54
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- public-domain
- creativecommons.org/publicdomain/zero/1.0/ (vor)
- Locations
- PLoS ONE (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (ZIAHL006012)
- National Institute of Diabetes and Digestive and Kidney Diseases
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Hematology › Blood groups and transfusion
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
- Keywords
- hydroxyurea, sickle cell disease, fetal hemoglobin, organ damage, survival, liver dysfunction, renal dysfunction, cardiopulmonary dysfunction, alkaline phosphatase, creatinine, adults with sickle cell disease, hydroxyurea resistance, hydroxyurea intolerance
- MeSH terms
- Adolescent, Adult, Aged, Anemia, Sickle Cell, Antisickling Agents, Female, Fetal Hemoglobin, Humans, Hydroxyurea, Male, Middle Aged, Retrospective Studies, Proportional Hazards Models, Treatment Outcome, Maximum Tolerated Dose, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.